BACKGROUND: We recently observed a significant CD4 cell count decline in patients receiving didanosine (ddI) 400 mg, tenofovir (TDF) and nevirapine (NVP), despite virological suppression. METHODS: We identified from our computerized patient database subjects who initiated combinations containing ddI and/or TDF for reasons other than virological failure, including simplification or intolerance. Changes in total, CD4+ and CD8+ lymphocyte counts since the initiation of therapy were analysed retrospectively. Plasma concentration of ddI was prospectively determined in eight of these patients receiving ddI 400 mg + TDF + NVP and 3 weeks after a ddI dosage reduction. RESULTS: A total of 302 patients were studied. A significant decrease in CD4 and CD8 and in total lymphocyte counts was only seen in subjects receiving ddI standard dose + TDF-containing regimens, despite the maintenance of viral suppression. More than 50% of these patients showed a decline of more than 100 CD4 cells at 48 weeks. In contrast, subjects not receiving ddI + TDF together experienced the expected progressive increase in CD4 T-cell counts. Plasma levels of ddI were elevated in all patients receiving the standard ddI dose + TDF. DdI plasma levels significantly decreased when patients weighting > 60 kg reduced ddI dose to 250 mg, achieving similar levels to those generated by ddI 400 mg without TDF. CONCLUSIONS: Co-administration of ddI at standard doses plus TDF appears to exert a deleterious effect on CD4 and CD8 counts. Although lymphocyte toxicity related to excessive ddI plasma levels could explain our findings, other mechanisms cannot be excluded. Pharmacokinetic data suggest ddI dose reduction when coadministered with TDF.
BACKGROUND: We recently observed a significant CD4 cell count decline in patients receiving didanosine (ddI) 400 mg, tenofovir (TDF) and nevirapine (NVP), despite virological suppression. METHODS: We identified from our computerized patient database subjects who initiated combinations containing ddI and/or TDF for reasons other than virological failure, including simplification or intolerance. Changes in total, CD4+ and CD8+ lymphocyte counts since the initiation of therapy were analysed retrospectively. Plasma concentration of ddI was prospectively determined in eight of these patients receiving ddI 400 mg + TDF + NVP and 3 weeks after a ddI dosage reduction. RESULTS: A total of 302 patients were studied. A significant decrease in CD4 and CD8 and in total lymphocyte counts was only seen in subjects receiving ddI standard dose + TDF-containing regimens, despite the maintenance of viral suppression. More than 50% of these patients showed a decline of more than 100 CD4 cells at 48 weeks. In contrast, subjects not receiving ddI + TDF together experienced the expected progressive increase in CD4 T-cell counts. Plasma levels of ddI were elevated in all patients receiving the standard ddI dose + TDF. DdI plasma levels significantly decreased when patients weighting > 60 kg reduced ddI dose to 250 mg, achieving similar levels to those generated by ddI 400 mg without TDF. CONCLUSIONS: Co-administration of ddI at standard doses plus TDF appears to exert a deleterious effect on CD4 and CD8 counts. Although lymphocyte toxicity related to excessive ddI plasma levels could explain our findings, other mechanisms cannot be excluded. Pharmacokinetic data suggest ddI dose reduction when coadministered with TDF.
Authors: Alice Tseng; Michelle Foisy; Christine A Hughes; Deborah Kelly; Shanna Chan; Natalie Dayneka; Pierre Giguère; Niamh Higgins; Cara Hills-Nieminen; Jeff Kapler; Charles J L la Porte; Pam Nickel; Laura Park-Wyllie; Carlo Quaia; Linda Robinson; Nancy Sheehan; Shannon Stone; Linda Sulz; Deborah Yoong Journal: Can J Hosp Pharm Date: 2012-03
Authors: Trevor Hawkins; Wenoah Veikley; Lucie Durand-Gasselin; Darius Babusis; Y Sunila Reddy; John F Flaherty; Adrian S Ray Journal: Antimicrob Agents Chemother Date: 2011-01-31 Impact factor: 5.191
Authors: Zexun Zhou; John H Rodman; Patricia M Flynn; Brian L Robbins; Carrie K Wilcox; David Z D'Argenio Journal: Antimicrob Agents Chemother Date: 2006-08 Impact factor: 5.191
Authors: Ighovwerha Ofotokun; Anandi N Sheth; Sara E Sanford; Kirk A Easley; Neeta Shenvi; Kelly White; Molly E Eaton; Carlos Del Rio; Jeffrey L Lennox Journal: AIDS Res Hum Retroviruses Date: 2012-04-20 Impact factor: 2.205
Authors: Timothy J Wilkin; Christina M Lalama; John McKinnon; Rajesh T Gandhi; Nina Lin; Alan Landay; Heather Ribaudo; Lawrence Fox; Judith S Currier; John W Mellors; Roy Gulick; Allan R Tenorio Journal: J Infect Dis Date: 2012-06-27 Impact factor: 5.226
Authors: P Costa; F Bozzano; D Fenoglio; A Beltrame; G Cenderello; A Di Biagio; G Ferrea; G Pagano; A De Maria Journal: Clin Exp Immunol Date: 2009-10 Impact factor: 4.330
Authors: Elizabeth Nies-Kraske; Timothy W Schacker; David Condoluci; Jan Orenstein; Jason Brenchley; Cecil Fox; Marybeth Daucher; Robin Dewar; Elizabeth Urban; Brenna Hill; Javier Guenaga; Shelley Hoover; Frank Maldarelli; Claire W Hallahan; Judith Horn; Shyamasundaran Kottilil; Tae-Wook Chun; Marlene Folino; Sara Palmer; Ann Wiegand; M Angeline O'Shea; Julia A Metcalf; Daniel C Douek; John Coffin; Ashley Haase; Anthony S Fauci; Mark Dybul Journal: J Infect Dis Date: 2009-06-01 Impact factor: 5.226